DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Ulcerative Colitis – Access & Reimbursement – Access & Reimbursement – Ulcerative Colitis (US)
TNF-alpha inhibitors (e.g., Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira) are entrenched in the U.S. ulcerative colitis (UC) therapy market. Alternative treatment options…
Neuromyelitis Optica Spectrum Disorder | Current Treatment: Physician Insights | US | 2025
NMOSD is a rare, chronic neuroinflammatory disorder marked by optic neuritis and longitudinal extensive transverse myelitis, often leading to repeated attacks and accumulating neurological damage…
Gene Therapy – Access & Reimbursement – Access & Reimbursement – Gene Therapies for Rare Diseases (US)
Given the availability of an increasing number of approved innovative, high-cost gene therapies, value assessment and novel approaches to reimbursement are rapidly gaining importance. To assist…
Acute Lymphoblastic Leukemia – Current Treatment – Treatment Sequencing – Acute Lymphoblastic Leukemia (US)
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…
Hemophilia A – Current Treatment – Current Treatment: Physician Insights – Hemophilia A (US)
Hemophilia A is a monogenic X-linked recessive bleeding disorder caused by the deficiency of clotting factor VIII. Prophylaxis, the typical care for hemophilia A patients, is especially preferred…
